Abe, Y.; Hamasaki, T.; Natsume, J.; Mogami, Y.; Murayama, K.; Shiraishi, H.; Abe, Y.; Kumada, S.; Tanaka, R.; Ihara, K.;
et al. Efficacy and Safety of 5-Aminolevulinic Acid Hydrochloride Combined with Sodium Ferrous Citrate in Pediatric Patients with Leigh Syndrome and Central Nervous System Disorders: An Initial Exploratory Trial with a Double-Blind Placebo-Controlled Period, Followed by an Open-Label Period and a Subsequent Long-Term Administration Study. Life 2025, 15, 1168.
https://doi.org/10.3390/life15081168
AMA Style
Abe Y, Hamasaki T, Natsume J, Mogami Y, Murayama K, Shiraishi H, Abe Y, Kumada S, Tanaka R, Ihara K,
et al. Efficacy and Safety of 5-Aminolevulinic Acid Hydrochloride Combined with Sodium Ferrous Citrate in Pediatric Patients with Leigh Syndrome and Central Nervous System Disorders: An Initial Exploratory Trial with a Double-Blind Placebo-Controlled Period, Followed by an Open-Label Period and a Subsequent Long-Term Administration Study. Life. 2025; 15(8):1168.
https://doi.org/10.3390/life15081168
Chicago/Turabian Style
Abe, Yuichi, Toshimitsu Hamasaki, Jun Natsume, Yukiko Mogami, Kei Murayama, Hideaki Shiraishi, Yuki Abe, Satoko Kumada, Ryuta Tanaka, Kenji Ihara,
and et al. 2025. "Efficacy and Safety of 5-Aminolevulinic Acid Hydrochloride Combined with Sodium Ferrous Citrate in Pediatric Patients with Leigh Syndrome and Central Nervous System Disorders: An Initial Exploratory Trial with a Double-Blind Placebo-Controlled Period, Followed by an Open-Label Period and a Subsequent Long-Term Administration Study" Life 15, no. 8: 1168.
https://doi.org/10.3390/life15081168
APA Style
Abe, Y., Hamasaki, T., Natsume, J., Mogami, Y., Murayama, K., Shiraishi, H., Abe, Y., Kumada, S., Tanaka, R., Ihara, K., Sakakibara, T., Okazaki, Y., Nakagawa, H., Takahashi, K., Yamauchi, M., Nakajima, M., & Ohtake, A.
(2025). Efficacy and Safety of 5-Aminolevulinic Acid Hydrochloride Combined with Sodium Ferrous Citrate in Pediatric Patients with Leigh Syndrome and Central Nervous System Disorders: An Initial Exploratory Trial with a Double-Blind Placebo-Controlled Period, Followed by an Open-Label Period and a Subsequent Long-Term Administration Study. Life, 15(8), 1168.
https://doi.org/10.3390/life15081168
